Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel
25 Mai 2016 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the Company”), an
oncology-focused biotechnology company, today announces that the
United States Patent and Trademark Office has issued U.S. Patent
No. 9,345,718 on May 24, 2016, which covers CLR 1603, a
phospholipid ether-paclitaxel conjugate.
This specific PDC product patent is based on one of a series of
patent applications designed to protect both composition of matter
and method of use for phospholipid drug conjugates, or PDCs,
developed with Cellectar’s proprietary phospholipid-ether delivery
vehicle conjugated with any existing or future cytotoxic agents,
including chemotherapeutics such as paclitaxel, for targeted
delivery to cancer cells and cancer stem cells. Phospholipid
ethers act as a cancer targeting drug vehicle delivering cytotoxic
compounds like paclitaxel directly to cancer cells, thus limiting
the drug’s exposure to healthy cells and increasing the potency of
the drug at lower concentrations.
“This first issued patent under our CLR CTX Chemotherapeutic
program provides Cellectar and any future partners intellectual
property (IP) protection through at least November 2035, allowing
significant runway for product development and commercialization,”
said Jim Caruso, president and CEO of Cellectar.
“Importantly, this IP protection further validates our
delivery platform and strengthens the value-optimizing potential of
our CLR CTX chemotherapeutic conjugate R&D program.”
The objective of the CLR CTX franchise is to develop PDC
chemotherapeutics through conjugation of non-targeted anti-cancer
agents with the Company’s novel delivery vehicle with the goal of
improving therapeutic indices, enhancing product profiles and
expanding potential indications through targeted cancer cell
delivery of chemotherapeutic payloads.
About Phospholipid Drug Conjugates (PDCs)
Cellectar's PDC platform has demonstrated highly selective
cancer targeting both preclinically in over 60 in vivo cancer
models, and subsequently confirmed clinically in over 10 cancer
types. The platform's payload diversity has been validated using
cytotoxic radioisotopes for cancer therapy; PET imaging isotopes
for cancer imaging; fluorophores for image-guided surgery, and the
company has recently expanded its payload portfolio to
chemotherapeutics with further research of paclitaxel and other
non-targeted anti-cancer agents through both in-house and
collaborative R&D efforts.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC Delivery Platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules
have demonstrated highly selective uptake and retention in a broad
range of cancers. Cellectar's PDC pipeline includes product
candidates for cancer therapy and cancer diagnostic imaging. The
company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a
cytotoxic radioisotope, as its payload. CLR 131 is currently being
evaluated under an orphan drug designated Phase 1 study in patients
with relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1603-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form 10-K
for the year ended December 31, 2015. These forward-looking
statements are made only as of the date hereof, and we disclaim any
obligation to update any such forward-looking statements.
INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Aug 2023 bis Aug 2024